220 related articles for article (PubMed ID: 29559498)
1. Post-partum and non-post-partum relapsing Graves' hyperthyroidism display different response to anti-thyroid drugs.
Rotondi M; Capelli V; Coperchini F; Pinto S; Croce L; Tonacchera M; Chiovato L
Eur J Endocrinol; 2018 Jun; 178(6):589-594. PubMed ID: 29559498
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
[TBL] [Abstract][Full Text] [Related]
3. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.
Mazza E; Carlini M; Flecchia D; Blatto A; Zuccarini O; Gamba S; Beninati S; Messina M
J Endocrinol Invest; 2008 Oct; 31(10):866-72. PubMed ID: 19092290
[TBL] [Abstract][Full Text] [Related]
5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
6. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
7. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
9. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
[TBL] [Abstract][Full Text] [Related]
10. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
11. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy.
Rotondi M; Cappelli C; Pirali B; Pirola I; Magri F; Fonte R; Castellano M; Rosei EA; Chiovato L
J Clin Endocrinol Metab; 2008 Oct; 93(10):3985-8. PubMed ID: 18664537
[TBL] [Abstract][Full Text] [Related]
12. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
Liu C; Duan Y; Wu X
Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
[TBL] [Abstract][Full Text] [Related]
13. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
14. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.
Xu B; Wu D; Ying H; Zhang Y
Turk J Med Sci; 2019 Jun; 49(3):715-722. PubMed ID: 31023005
[TBL] [Abstract][Full Text] [Related]
15. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
16. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial.
Azizi F; Abdi H; Amouzegar A
BMC Endocr Disord; 2021 Jan; 21(1):16. PubMed ID: 33446181
[TBL] [Abstract][Full Text] [Related]
17. Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone.
Mao XM; Li HQ; Li Q; Li DM; Xie XJ; Yin GP; Zhang P; Xu XH; Wu JD; Chen SW; Wang SK
J Clin Endocrinol Metab; 2009 Dec; 94(12):4984-91. PubMed ID: 19850691
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the medical treatment of Graves' disease (GD)].
Peixoto MC; Coeli CM; Vaisman M
Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
